Erratum: Return of FEV1 after pulmonary exacerbation in children with cystic fibrosis (Pediatric Pulmonology (2010) 45, 2 (127-134) DOI: 10.1002/ppul.21117);Return of FEV1 after pulmonary exacerbation in children with cystic fibrosis

Pediatric Pulmonology

Volumn 45, Issue 2, 2010, Pages 127-134

  Sanders, Don B ^a   Hoffman, Lucas R ^a   Emerson, Julia ^a   Gibson, Ronald L ^a   Rosenfeld, Margaret ^a   Redding, Gregory J ^a   Goss, Christopher H ^a,b  

^a International Society for the Scholarship of Teaching and Learning   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Antibiotics; Cystic fibrosis; Pulmonary exacerbation; Pulmonary function tests; Spirometry

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; CORTICOSTEROID; DORNASE ALFA; MACROLIDE; MEROPENEM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOBRAMYCIN; ANTIINFECTIVE AGENT;

ADD ON THERAPY; ADOLESCENT; ANTIBIOTIC THERAPY; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLOMA; ASTHMA; CASE CONTROL STUDY; CHILD; CONTROLLED STUDY; CONVALESCENCE; CYSTIC FIBROSIS; DISEASE EXACERBATION; DRUG TREATMENT FAILURE; FEMALE; FORCED EXPIRATORY VOLUME; HOSPITALIZED CHILD; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAID; PEDIATRIC HOSPITAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; SCHOOL CHILD; TREATMENT OUTCOME; TREATMENT RESPONSE; BACTERIAL INFECTION; DISEASE COURSE; HOSPITALIZATION; MICROBIOLOGY; PATHOPHYSIOLOGY; UNITED STATES;

ADOLESCENT; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CHILD; CYSTIC FIBROSIS; DISEASE PROGRESSION; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; WASHINGTON;

EID: 75849154666     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.21249     Document Type: Erratum

References (15)

1. Ferkol T, Rosenfeld M, Milla CE. Cystic fibrosis pulmonary exacerbations. J Pediatr 2006;148:259-264.
2. Cystic Fibrosis Foundation. 2008. Patient Registry 2007 Annual Report. 10-25-2008. Bethesda, Maryland.
3. Liou TG, Adler FR, Fitzsimmons SC, Cahill BC, Hibbs JR, Marshall BC. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 2001;153:345-352.
4. Lieu TA, Ray GT, Farmer G, Shay GF. The cost of medical care for patients with cystic fibrosis in a health maintenance organization. Pediatrics 1999;103:e72.
5. Britto MT, Kotagal UR, Hornung RW, Atherton HD, Tsevat J, Wilmott RW. Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. Chest 2002;121:64-72.
6. Ramsey BW. Management of pulmonary disease in patients with cystic fibrosis. N Engl J Med 1996;335:179-188.
7. Smith AL, Fiel SB, Mayer-Hamblett N, Ramsey B, Burns JL. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest 2003;123:1495-1502.
8. Ordoñez CL, Henig NR, Mayer-Hamblett N, Accurso FJ, Burns JL, Chmiel JF, Daines CL, Gibson RL, McNamara S, Retsch-Bogart GZ, Zeitlin PL, Aitken ML. Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis. Am J Respir Crit Care Med 2003;168:1471-1475.
9. Gozal D, Bailey SL, Keens TG. Evolution of pulmonary function during an acute exacerbation in hospitalized patients with cystic fibrosis. Pediatr Pulmonol 1993;16:347-353.
10. 1 after pulmonary exacerbations in children with cystic fibrosis [abstract]. Am J Resp Crit Care Med 2008;177:A774.
11. Schechter MS, Shelton BJ, Margolis PA, Fitzsimmons SC. The association of socioeconomic status with outcomes in cystic fibrosis patients in the United States. Am J Respir Crit Care Med 2001;163:1331-1337.
12. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infection in cystic fibrosis. Am J Respir Crit Care Med 2003;168:918-951.
13. Knudson RJ, Lebowitz MD, Holberg CJ, Burrows B. Changes in the normal maximal expiratory flow - volume curve with growth and aging. Am Rev Respir Dis 1983;127:725-734.
14. Cunningham S, McColm JR, Mallinson A, Boyd I, Marshall TG. Duration of effect of intravenous antibiotics on spirometry and sputum cytokines in children with cystic fibrosis. Pediatr Pulmonol 2006;36:43-48.
15. Konstan MW, Morgan WJ, Butler SM, Pasta DJ, Craib ML, Silva SJ, Stokes DC, Wohl MEB, Wagener JS, Regelmann WE, Johnson CA. Risk factors for decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr 2007;151:134-139.